Clinical trials: Neoplasms Recurrence
Cervical Cancer
Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
This study is an open-label, multicenter, multinational, two-arm, parallel randomized Phase 3 study evaluating the efficacy and safety of S-1+Cisplatin versus single-agent Cisplatin in patients with stage IVB, recurrent or…
- Trial name
- NCT00770874
- Testing
- S-1 + Cisplatin (arm A), Cisplatin (arm B)
- Where
- 4 sites in Japan, South Korea and 1 more
- Volunteers
- 375 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Lymphoma
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00851552
- Testing
- rituximab, bortezomib, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of laboratory treated T cells to see how well they work in treating patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or acute lymphoblastic leukemia…
- Conditions
- CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT01865617
- Testing
- Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of pomalidomide in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma.
- Trial name
- NCT02011113
- Testing
- Pomalidomide, Dexamethasone
- Where
- 14 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Celgene Corporation
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
This study will examine the effects of an investigational drug called AT-101 in combination with an FDA approved cancer drug called Docetaxel.
- Trial name
- NCT01285635
- Testing
- AT-101, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of Michigan Rogel Cancer Center
Melanoma
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
To determine the safety and efficacy of the combination of HDI and anti-CTLA-4 monoclonal antibody for patients with recurrent inoperable stage III or stage IV melanoma.
- Trial name
- NCT00610857
- Testing
- Anti-CTLA4 monoclonal antibody and HDI
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Ahmad Tarhini
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Bortezomib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with pemetrexed disodium may kill more tumor cells.
- Trial name
- NCT00389805
- Testing
- bortezomib, pemetrexed disodium, gene expression analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Davis
Breast Cancer, Neoplasm Metastasis
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
This research is being done to find out how safe and how well the combination of lapatinib and vorinostat works against advanced cancers.
- Trial name
- NCT01118975
- Testing
- Vorinostat, Lapatinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Maryland, Baltimore
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
High-Dose Stereotactic Radiation for Prostate Cancer
This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01664130
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00621686
- Testing
- bevacizumab, sorafenib tosylate
- Where
- 204 sites in United States
- Volunteers
- 54 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
This randomized phase II trial studies how well capecitabine and bevacizumab with or without atezolizumab work in treating patients with colorectal cancer that is not responding to treatment and has spread to other places.
- Conditions
- Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7
- Trial name
- NCT02873195
- Testing
- Atezolizumab, Bevacizumab, Capecitabine
- Where
- 10 sites in United States
- Volunteers
- 133 people
- Sponsor
- Academic and Community Cancer Research United
Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy
Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
This is a single arm open label phase 2 study evaluating the potential effect of ixazomib on the prevention of recurrent or late acute graft-versus-host disease (GVHD) and chronic GVHD at 1-year following reduced intensity (RI)…
- Trial name
- NCT03082677
- Testing
- Ixazomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed Acute Myelogenous Leukemia
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs.
- Trial name
- NCT00939653
- Testing
- Clofarabine, Etoposide, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
This phase II trial studies the safety and feasibility of utilizing acupuncture in patients with high-risk bladder cancer that has not spread to the surrounding muscle (non-muscle invasive) undergoing treatment with Intravesical…
- Conditions
- Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
- Trial name
- NCT04496219
- Testing
- Acupuncture Therapy, BCG Solution, Best Practice
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Glioblastoma or Other Glioma Subtypes
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to adult patients with histologically confirmed GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating…
- Trial name
- NCT01975701
- Testing
- BGJ398
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Paraganglioma, Pheochromocytoma
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
This is an open-label phase II study of an investigational drug, sunitinib malate in patients with advanced malignant paraganglioma or phaeochromocytoma cancer.
- Trial name
- SNIPP (NCT00843037)
- Testing
- Sunitinib
- Where
- 4 sites in Canada, Netherlands
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
Head and Neck Cancer
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
- Trial name
- CheckMate 651 (NCT02741570)
- Testing
- Nivolumab, Ipilimumab, Cetuximab/Erbitux
- Where
- 133 sites in United States, Australia and 16 more
- Volunteers
- 947 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Cervical Cancer, Recurrent Vaginal Cancer
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
This phase II trial is studying how triapine and cisplatin given together with radiation therapy works in treating patients with cervical cancer or vaginal cancer.
- Conditions
- Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer
- Trial name
- NCT00941070
- Testing
- triapine, cisplatin, external beam radiation therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Phase II trial to study the effectiveness of neoadjuvant and adjuvant imatinib mesylate in treating patients who are undergoing surgery for primary or recurrent malignant gastrointestinal stromal tumor.
- Trial name
- NCT00028002
- Testing
- Conventional Surgery, Imatinib Mesylate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, HIV Infection
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
This phase I trial studies the side effects and best dose of cabozantinib s-malate in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment and…
- Conditions
- Advanced Malignant Solid Neoplasm, HIV Infection, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT01822522
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 20 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)